{
    "id": 24824,
    "fullName": "MTOR A2034V",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MTOR A2034V lies within the FKBP-rapamycin binding domain of the Mtor protein (PMID: 27279227). A2034V results in the loss of mTOR's ability to bind rapamycin analogs (PMID: 27279227).",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "A2034V",
    "createDate": "07/26/2016",
    "updateDate": "11/04/2016",
    "referenceTranscriptCoordinates": {
        "id": 145086,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11127739G>A",
        "cDna": "c.6101C>T",
        "protein": "p.A2034V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7497,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing MTOR A2034V demonstrated sensitivity to treatment with AZD8055 in xenograft models, resulting in decreased tumor volume (PMID: 27279227).",
            "molecularProfile": {
                "id": 25581,
                "profileName": "MTOR A2034V"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7490,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line treated with Rapamune (sirolimus) demonstrated resistance after three months of treatment due to the acquired resistance mutation, MTOR A2034V (PMID: 27279227).",
            "molecularProfile": {
                "id": 25581,
                "profileName": "MTOR A2034V"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7498,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing MTOR A2034V demonstrated sensitivity to treatment with RapaLink-1 in xenograft models, resulting in decreased tumor volume (PMID: 27279227).",
            "molecularProfile": {
                "id": 25581,
                "profileName": "MTOR A2034V"
            },
            "therapy": {
                "id": 4493,
                "therapyName": "RapaLink-1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25581,
            "profileName": "MTOR A2034V",
            "profileTreatmentApproaches": [
                {
                    "id": 10792,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR A2034V"
                },
                {
                    "id": 10793,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR A2034V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145087,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11127739G>A",
            "cDna": "c.6101C>T",
            "protein": "p.A2034V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145086,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11127739G>A",
            "cDna": "c.6101C>T",
            "protein": "p.A2034V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}